For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View

Sponsor Spike Success.

Nvidia Invests in Generate Biomedicines to Enhance AI Drug Discovery

Jun 27, 2026
Nvidia Invests in Generate Biomedicines to Enhance AI Drug Discovery

's venture arm, NVentures, has disclosed ownership of 833,325 shares in Generate Biomedicines, valued at around $10.4 million, according to Nvidia's latest 13F filing from May 2026. Generate, listed on Nasdaq under the ticker GENB, is focused on creating an -powered platform that automates the generation and optimization of therapeutic proteins, aiming to significantly shorten the drug discovery timeline.

The company employs generative AI models to design proteins and drug candidates from the ground up. Currently, Generate is advancing beyond theoretical applications, with a Phase 3 clinical trial for severe asthma underway, which is the final testing phase before seeking regulatory approval. Additionally, it has multiple oncology candidates that have received FDA Fast Track designation, a status granted to treatments addressing serious conditions with unmet medical needs.

For Your Trading Desk
Trading Journals
Click For Trade View
Desk Accessories
Click For Trade View

Sponsor Spike Success.

Since its inception, Generate has raised approximately $700 million in funding. NVentures first participated during Generate's $273 million Series C funding round, which concluded in September 2023 and included contributions from Amgen, a leading biotech firm. Generate went public with a Nasdaq IPO in February 2026.

While a $10.4 million stake may seem minor for a company of Nvidia's scale, this is part of Nvidia's broader strategy to cultivate a customer ecosystem that will rely on its chips for years to come. The drug discovery process, which includes simulating protein folding and predicting molecular interactions with human biology, requires the parallel processing capabilities that Nvidia's hardware is designed to provide.

However, the investment carries risks. As a clinical-stage company, Generate has yet to generate significant revenue from approved products. Phase 3 trials can fail, and Fast Track designation does not guarantee approval. The $700 million raised will need to sustain the company through potentially lengthy clinical processes.

For investors in Nvidia or related AI infrastructure, Generate's progress in clinical trials is an important metric to monitor. A successful Phase 3 outcome for the severe asthma program could not only impact GENB's stock but also reinforce the notion that AI-driven computing is becoming essential across various industries, supporting Nvidia's growth narrative.

For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View
Trading Journals

Log entries, exits, and the reason you clicked. 'It looked promising' deserves a second look.

Click For Trade View

Sponsor Spike Success.

Recommended for You
Nvidia Stock Recovery Potential Amid Leadership Scandal
Tech Stocks Nov 16, 2026

Nvidia Stock Recovery Potential Amid Leadership Scandal

Nvidia's stock saw a significant drop last week due to the Jensen Huang scandal, but analysts suggest a potential rebound. Currently…

For Your Trading Desk
Trading Books

Price action, trading discipline, and the homework behind decisions made in seconds.

Click For Trade View
Trading Journals

Log entries, exits, and the reason you clicked. 'It looked promising' deserves a second look.

Click For Trade View
Desk Accessories

Monitor stands and desk organizers for a trading setup with fewer loose ends.

Click For Trade View
Market Microstructure & Order Flow

Books on liquidity, order books, spreads, and trade execution. A closer look at what happens between clicking and getting filled.

Click For Trade View
Algorithmic Trading & Python

Coding and research books for systematic traders. Backtests deserve scrutiny, not a victory lap.

Click For Trade View
Financial Statements & Earnings Research

References for reading earnings reports, cash flow, and balance sheets. The headline rarely brings all the footnotes.

Click For Trade View

Sponsor Spike Success.

Across our publications

In Other News

Latest stories from other publications.

Explore all publications (opens in a new tab)